Global Allergy Immunotherapy

Allergy Immunotherapy Comprehensive Study by Type (Allergy Shots, Sublingual Immunotherapy, Medications, Intranasal Immunotherapy), Allergy Type (Asthma, Allergic Rhinitis, Atopic Dermatitis, Seasonal Allergies, Insect Venom Allergy, Food Allergy, Others), Sales Channel (Online, Offline), Allergen (Pollen, Mold/Fungi, Animal Dander, Dust Mites, Insects Venom (Bees, Wasps, Hornets, Yellow Jackets), Others) Players and Region - Global Market Outlook to 2028

Allergy Immunotherapy Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Allergy Immunotherapy Market Overview:
The Global Allergy Immunotherapy market was valued at USD 2,050.90 Million in 2022and is expected to reach USD 3,703.4 Million by 2028, growing at a CAGR of xxx % during 2023- 2028.

AttributesDetails
Study Period2018-2028
Base Year2022
Forecast Period2023-2028
Historical Period2018-2022
UnitValue (USD Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility

Competitive Landscape:

Some of the key players profiled in the report are ALK, HAL Allergy Group, Merck KGaA?Allergopharma?, Stallergenes Greer, Circassia, DBV Technologies., Aimmune Therapeutics, Biomay AG, Anergis and Allergy Therapeutics. Considering Market by Allergy Type, the sub-segment i.e. Asthma will boost the Allergy Immunotherapy market. Considering Market by Sales Channel, the sub-segment i.e. Online will boost the Allergy Immunotherapy market. Considering Market by Allergen, the sub-segment i.e. Pollen will boost the Allergy Immunotherapy market.

What Can be Explored with the Allergy Immunotherapy Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Allergy Immunotherapy Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Allergy Immunotherapy
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Allergy Immunotherapy market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Allergy Immunotherapy market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Type
  • Allergy Shots
  • Sublingual Immunotherapy
  • Medications
  • Intranasal Immunotherapy
By Allergy Type
  • Asthma
  • Allergic Rhinitis
  • Atopic Dermatitis
  • Seasonal Allergies
  • Insect Venom Allergy
  • Food Allergy
  • Others

By Sales Channel
  • Online
  • Offline

By Allergen
  • Pollen
  • Mold/Fungi
  • Animal Dander
  • Dust Mites
  • Insects Venom (Bees, Wasps, Hornets, Yellow Jackets)
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Factor Analysis
    • 3.1. Porters Five Forces
    • 3.2. Supply/Value Chain
    • 3.3. PESTEL analysis
    • 3.4. Market Entropy
    • 3.5. Patent/Trademark Analysis
  • 4. Global Allergy Immunotherapy, by Type, Allergy Type, Sales Channel, Allergen and Region (value) (2017-2022)
    • 4.1. Introduction
    • 4.2. Global Allergy Immunotherapy (Value)
      • 4.2.1. Global Allergy Immunotherapy by: Type (Value)
        • 4.2.1.1. Allergy Shots
        • 4.2.1.2. Sublingual Immunotherapy
        • 4.2.1.3. Medications
        • 4.2.1.4. Intranasal Immunotherapy
      • 4.2.2. Global Allergy Immunotherapy by: Allergy Type (Value)
        • 4.2.2.1. Asthma
        • 4.2.2.2. Allergic Rhinitis
        • 4.2.2.3. Atopic Dermatitis
        • 4.2.2.4. Seasonal Allergies
        • 4.2.2.5. Insect Venom Allergy
        • 4.2.2.6. Food Allergy
        • 4.2.2.7. Others
      • 4.2.3. Global Allergy Immunotherapy by: Sales Channel (Value)
        • 4.2.3.1. Online
        • 4.2.3.2. Offline
      • 4.2.4. Global Allergy Immunotherapy by: Allergen (Value)
        • 4.2.4.1. Pollen
        • 4.2.4.2. Mold/Fungi
        • 4.2.4.3. Animal Dander
        • 4.2.4.4. Dust Mites
        • 4.2.4.5. Insects Venom (Bees, Wasps, Hornets, Yellow Jackets)
        • 4.2.4.6. Others
      • 4.2.5. Global Allergy Immunotherapy Region
        • 4.2.5.1. South America
          • 4.2.5.1.1. Brazil
          • 4.2.5.1.2. Argentina
          • 4.2.5.1.3. Rest of South America
        • 4.2.5.2. Asia Pacific
          • 4.2.5.2.1. China
          • 4.2.5.2.2. Japan
          • 4.2.5.2.3. India
          • 4.2.5.2.4. South Korea
          • 4.2.5.2.5. Taiwan
          • 4.2.5.2.6. Australia
          • 4.2.5.2.7. Rest of Asia-Pacific
        • 4.2.5.3. Europe
          • 4.2.5.3.1. Germany
          • 4.2.5.3.2. France
          • 4.2.5.3.3. Italy
          • 4.2.5.3.4. United Kingdom
          • 4.2.5.3.5. Netherlands
          • 4.2.5.3.6. Rest of Europe
        • 4.2.5.4. MEA
          • 4.2.5.4.1. Middle East
          • 4.2.5.4.2. Africa
        • 4.2.5.5. North America
          • 4.2.5.5.1. United States
          • 4.2.5.5.2. Canada
          • 4.2.5.5.3. Mexico
  • 5. Allergy Immunotherapy: Manufacturers/Players Analysis
    • 5.1. Competitive Landscape
      • 5.1.1. Market Share Analysis
        • 5.1.1.1. Top 3
        • 5.1.1.2. Top 5
    • 5.2. Peer Group Analysis (2022)
    • 5.3. BCG Matrix
    • 5.4. Company Profile
      • 5.4.1. ALK
        • 5.4.1.1. Business Overview
        • 5.4.1.2. Products/Services Offerings
        • 5.4.1.3. Financial Analysis
        • 5.4.1.4. SWOT Analysis
      • 5.4.2. HAL Allergy Group
        • 5.4.2.1. Business Overview
        • 5.4.2.2. Products/Services Offerings
        • 5.4.2.3. Financial Analysis
        • 5.4.2.4. SWOT Analysis
      • 5.4.3. Merck KGaA?Allergopharma?
        • 5.4.3.1. Business Overview
        • 5.4.3.2. Products/Services Offerings
        • 5.4.3.3. Financial Analysis
        • 5.4.3.4. SWOT Analysis
      • 5.4.4. Stallergenes Greer
        • 5.4.4.1. Business Overview
        • 5.4.4.2. Products/Services Offerings
        • 5.4.4.3. Financial Analysis
        • 5.4.4.4. SWOT Analysis
      • 5.4.5. Circassia
        • 5.4.5.1. Business Overview
        • 5.4.5.2. Products/Services Offerings
        • 5.4.5.3. Financial Analysis
        • 5.4.5.4. SWOT Analysis
      • 5.4.6. DBV Technologies.
        • 5.4.6.1. Business Overview
        • 5.4.6.2. Products/Services Offerings
        • 5.4.6.3. Financial Analysis
        • 5.4.6.4. SWOT Analysis
      • 5.4.7. Aimmune Therapeutics
        • 5.4.7.1. Business Overview
        • 5.4.7.2. Products/Services Offerings
        • 5.4.7.3. Financial Analysis
        • 5.4.7.4. SWOT Analysis
      • 5.4.8. Biomay AG
        • 5.4.8.1. Business Overview
        • 5.4.8.2. Products/Services Offerings
        • 5.4.8.3. Financial Analysis
        • 5.4.8.4. SWOT Analysis
      • 5.4.9. Anergis
        • 5.4.9.1. Business Overview
        • 5.4.9.2. Products/Services Offerings
        • 5.4.9.3. Financial Analysis
        • 5.4.9.4. SWOT Analysis
      • 5.4.10. Allergy Therapeutics
        • 5.4.10.1. Business Overview
        • 5.4.10.2. Products/Services Offerings
        • 5.4.10.3. Financial Analysis
        • 5.4.10.4. SWOT Analysis
  • 6. Global Allergy Immunotherapy Sale, by Type, Allergy Type, Sales Channel, Allergen and Region (value) (2023-2028)
    • 6.1. Introduction
    • 6.2. Global Allergy Immunotherapy (Value)
      • 6.2.1. Global Allergy Immunotherapy by: Type (Value)
        • 6.2.1.1. Allergy Shots
        • 6.2.1.2. Sublingual Immunotherapy
        • 6.2.1.3. Medications
        • 6.2.1.4. Intranasal Immunotherapy
      • 6.2.2. Global Allergy Immunotherapy by: Allergy Type (Value)
        • 6.2.2.1. Asthma
        • 6.2.2.2. Allergic Rhinitis
        • 6.2.2.3. Atopic Dermatitis
        • 6.2.2.4. Seasonal Allergies
        • 6.2.2.5. Insect Venom Allergy
        • 6.2.2.6. Food Allergy
        • 6.2.2.7. Others
      • 6.2.3. Global Allergy Immunotherapy by: Sales Channel (Value)
        • 6.2.3.1. Online
        • 6.2.3.2. Offline
      • 6.2.4. Global Allergy Immunotherapy by: Allergen (Value)
        • 6.2.4.1. Pollen
        • 6.2.4.2. Mold/Fungi
        • 6.2.4.3. Animal Dander
        • 6.2.4.4. Dust Mites
        • 6.2.4.5. Insects Venom (Bees, Wasps, Hornets, Yellow Jackets)
        • 6.2.4.6. Others
      • 6.2.5. Global Allergy Immunotherapy Region
        • 6.2.5.1. South America
          • 6.2.5.1.1. Brazil
          • 6.2.5.1.2. Argentina
          • 6.2.5.1.3. Rest of South America
        • 6.2.5.2. Asia Pacific
          • 6.2.5.2.1. China
          • 6.2.5.2.2. Japan
          • 6.2.5.2.3. India
          • 6.2.5.2.4. South Korea
          • 6.2.5.2.5. Taiwan
          • 6.2.5.2.6. Australia
          • 6.2.5.2.7. Rest of Asia-Pacific
        • 6.2.5.3. Europe
          • 6.2.5.3.1. Germany
          • 6.2.5.3.2. France
          • 6.2.5.3.3. Italy
          • 6.2.5.3.4. United Kingdom
          • 6.2.5.3.5. Netherlands
          • 6.2.5.3.6. Rest of Europe
        • 6.2.5.4. MEA
          • 6.2.5.4.1. Middle East
          • 6.2.5.4.2. Africa
        • 6.2.5.5. North America
          • 6.2.5.5.1. United States
          • 6.2.5.5.2. Canada
          • 6.2.5.5.3. Mexico
  • 7. Appendix
    • 7.1. Acronyms
  • 8. Methodology and Data Source
    • 8.1. Methodology/Research Approach
      • 8.1.1. Research Programs/Design
      • 8.1.2. Market Size Estimation
      • 8.1.3. Market Breakdown and Data Triangulation
    • 8.2. Data Source
      • 8.2.1. Secondary Sources
      • 8.2.2. Primary Sources
    • 8.3. Disclaimer
List of Tables
  • Table 1. Allergy Immunotherapy: by Type(USD Million)
  • Table 2. Allergy Immunotherapy Allergy Shots , by Region USD Million (2017-2022)
  • Table 3. Allergy Immunotherapy Sublingual Immunotherapy , by Region USD Million (2017-2022)
  • Table 4. Allergy Immunotherapy Medications , by Region USD Million (2017-2022)
  • Table 5. Allergy Immunotherapy Intranasal Immunotherapy , by Region USD Million (2017-2022)
  • Table 6. Allergy Immunotherapy: by Allergy Type(USD Million)
  • Table 7. Allergy Immunotherapy Asthma , by Region USD Million (2017-2022)
  • Table 8. Allergy Immunotherapy Allergic Rhinitis , by Region USD Million (2017-2022)
  • Table 9. Allergy Immunotherapy Atopic Dermatitis , by Region USD Million (2017-2022)
  • Table 10. Allergy Immunotherapy Seasonal Allergies , by Region USD Million (2017-2022)
  • Table 11. Allergy Immunotherapy Insect Venom Allergy , by Region USD Million (2017-2022)
  • Table 12. Allergy Immunotherapy Food Allergy , by Region USD Million (2017-2022)
  • Table 13. Allergy Immunotherapy Others , by Region USD Million (2017-2022)
  • Table 14. Allergy Immunotherapy: by Sales Channel(USD Million)
  • Table 15. Allergy Immunotherapy Online , by Region USD Million (2017-2022)
  • Table 16. Allergy Immunotherapy Offline , by Region USD Million (2017-2022)
  • Table 17. Allergy Immunotherapy: by Allergen(USD Million)
  • Table 18. Allergy Immunotherapy Pollen , by Region USD Million (2017-2022)
  • Table 19. Allergy Immunotherapy Mold/Fungi , by Region USD Million (2017-2022)
  • Table 20. Allergy Immunotherapy Animal Dander , by Region USD Million (2017-2022)
  • Table 21. Allergy Immunotherapy Dust Mites , by Region USD Million (2017-2022)
  • Table 22. Allergy Immunotherapy Insects Venom (Bees, Wasps, Hornets, Yellow Jackets) , by Region USD Million (2017-2022)
  • Table 23. Allergy Immunotherapy Others , by Region USD Million (2017-2022)
  • Table 24. South America Allergy Immunotherapy, by Country USD Million (2017-2022)
  • Table 25. South America Allergy Immunotherapy, by Type USD Million (2017-2022)
  • Table 26. South America Allergy Immunotherapy, by Allergy Type USD Million (2017-2022)
  • Table 27. South America Allergy Immunotherapy, by Sales Channel USD Million (2017-2022)
  • Table 28. South America Allergy Immunotherapy, by Allergen USD Million (2017-2022)
  • Table 29. Brazil Allergy Immunotherapy, by Type USD Million (2017-2022)
  • Table 30. Brazil Allergy Immunotherapy, by Allergy Type USD Million (2017-2022)
  • Table 31. Brazil Allergy Immunotherapy, by Sales Channel USD Million (2017-2022)
  • Table 32. Brazil Allergy Immunotherapy, by Allergen USD Million (2017-2022)
  • Table 33. Argentina Allergy Immunotherapy, by Type USD Million (2017-2022)
  • Table 34. Argentina Allergy Immunotherapy, by Allergy Type USD Million (2017-2022)
  • Table 35. Argentina Allergy Immunotherapy, by Sales Channel USD Million (2017-2022)
  • Table 36. Argentina Allergy Immunotherapy, by Allergen USD Million (2017-2022)
  • Table 37. Rest of South America Allergy Immunotherapy, by Type USD Million (2017-2022)
  • Table 38. Rest of South America Allergy Immunotherapy, by Allergy Type USD Million (2017-2022)
  • Table 39. Rest of South America Allergy Immunotherapy, by Sales Channel USD Million (2017-2022)
  • Table 40. Rest of South America Allergy Immunotherapy, by Allergen USD Million (2017-2022)
  • Table 41. Asia Pacific Allergy Immunotherapy, by Country USD Million (2017-2022)
  • Table 42. Asia Pacific Allergy Immunotherapy, by Type USD Million (2017-2022)
  • Table 43. Asia Pacific Allergy Immunotherapy, by Allergy Type USD Million (2017-2022)
  • Table 44. Asia Pacific Allergy Immunotherapy, by Sales Channel USD Million (2017-2022)
  • Table 45. Asia Pacific Allergy Immunotherapy, by Allergen USD Million (2017-2022)
  • Table 46. China Allergy Immunotherapy, by Type USD Million (2017-2022)
  • Table 47. China Allergy Immunotherapy, by Allergy Type USD Million (2017-2022)
  • Table 48. China Allergy Immunotherapy, by Sales Channel USD Million (2017-2022)
  • Table 49. China Allergy Immunotherapy, by Allergen USD Million (2017-2022)
  • Table 50. Japan Allergy Immunotherapy, by Type USD Million (2017-2022)
  • Table 51. Japan Allergy Immunotherapy, by Allergy Type USD Million (2017-2022)
  • Table 52. Japan Allergy Immunotherapy, by Sales Channel USD Million (2017-2022)
  • Table 53. Japan Allergy Immunotherapy, by Allergen USD Million (2017-2022)
  • Table 54. India Allergy Immunotherapy, by Type USD Million (2017-2022)
  • Table 55. India Allergy Immunotherapy, by Allergy Type USD Million (2017-2022)
  • Table 56. India Allergy Immunotherapy, by Sales Channel USD Million (2017-2022)
  • Table 57. India Allergy Immunotherapy, by Allergen USD Million (2017-2022)
  • Table 58. South Korea Allergy Immunotherapy, by Type USD Million (2017-2022)
  • Table 59. South Korea Allergy Immunotherapy, by Allergy Type USD Million (2017-2022)
  • Table 60. South Korea Allergy Immunotherapy, by Sales Channel USD Million (2017-2022)
  • Table 61. South Korea Allergy Immunotherapy, by Allergen USD Million (2017-2022)
  • Table 62. Taiwan Allergy Immunotherapy, by Type USD Million (2017-2022)
  • Table 63. Taiwan Allergy Immunotherapy, by Allergy Type USD Million (2017-2022)
  • Table 64. Taiwan Allergy Immunotherapy, by Sales Channel USD Million (2017-2022)
  • Table 65. Taiwan Allergy Immunotherapy, by Allergen USD Million (2017-2022)
  • Table 66. Australia Allergy Immunotherapy, by Type USD Million (2017-2022)
  • Table 67. Australia Allergy Immunotherapy, by Allergy Type USD Million (2017-2022)
  • Table 68. Australia Allergy Immunotherapy, by Sales Channel USD Million (2017-2022)
  • Table 69. Australia Allergy Immunotherapy, by Allergen USD Million (2017-2022)
  • Table 70. Rest of Asia-Pacific Allergy Immunotherapy, by Type USD Million (2017-2022)
  • Table 71. Rest of Asia-Pacific Allergy Immunotherapy, by Allergy Type USD Million (2017-2022)
  • Table 72. Rest of Asia-Pacific Allergy Immunotherapy, by Sales Channel USD Million (2017-2022)
  • Table 73. Rest of Asia-Pacific Allergy Immunotherapy, by Allergen USD Million (2017-2022)
  • Table 74. Europe Allergy Immunotherapy, by Country USD Million (2017-2022)
  • Table 75. Europe Allergy Immunotherapy, by Type USD Million (2017-2022)
  • Table 76. Europe Allergy Immunotherapy, by Allergy Type USD Million (2017-2022)
  • Table 77. Europe Allergy Immunotherapy, by Sales Channel USD Million (2017-2022)
  • Table 78. Europe Allergy Immunotherapy, by Allergen USD Million (2017-2022)
  • Table 79. Germany Allergy Immunotherapy, by Type USD Million (2017-2022)
  • Table 80. Germany Allergy Immunotherapy, by Allergy Type USD Million (2017-2022)
  • Table 81. Germany Allergy Immunotherapy, by Sales Channel USD Million (2017-2022)
  • Table 82. Germany Allergy Immunotherapy, by Allergen USD Million (2017-2022)
  • Table 83. France Allergy Immunotherapy, by Type USD Million (2017-2022)
  • Table 84. France Allergy Immunotherapy, by Allergy Type USD Million (2017-2022)
  • Table 85. France Allergy Immunotherapy, by Sales Channel USD Million (2017-2022)
  • Table 86. France Allergy Immunotherapy, by Allergen USD Million (2017-2022)
  • Table 87. Italy Allergy Immunotherapy, by Type USD Million (2017-2022)
  • Table 88. Italy Allergy Immunotherapy, by Allergy Type USD Million (2017-2022)
  • Table 89. Italy Allergy Immunotherapy, by Sales Channel USD Million (2017-2022)
  • Table 90. Italy Allergy Immunotherapy, by Allergen USD Million (2017-2022)
  • Table 91. United Kingdom Allergy Immunotherapy, by Type USD Million (2017-2022)
  • Table 92. United Kingdom Allergy Immunotherapy, by Allergy Type USD Million (2017-2022)
  • Table 93. United Kingdom Allergy Immunotherapy, by Sales Channel USD Million (2017-2022)
  • Table 94. United Kingdom Allergy Immunotherapy, by Allergen USD Million (2017-2022)
  • Table 95. Netherlands Allergy Immunotherapy, by Type USD Million (2017-2022)
  • Table 96. Netherlands Allergy Immunotherapy, by Allergy Type USD Million (2017-2022)
  • Table 97. Netherlands Allergy Immunotherapy, by Sales Channel USD Million (2017-2022)
  • Table 98. Netherlands Allergy Immunotherapy, by Allergen USD Million (2017-2022)
  • Table 99. Rest of Europe Allergy Immunotherapy, by Type USD Million (2017-2022)
  • Table 100. Rest of Europe Allergy Immunotherapy, by Allergy Type USD Million (2017-2022)
  • Table 101. Rest of Europe Allergy Immunotherapy, by Sales Channel USD Million (2017-2022)
  • Table 102. Rest of Europe Allergy Immunotherapy, by Allergen USD Million (2017-2022)
  • Table 103. MEA Allergy Immunotherapy, by Country USD Million (2017-2022)
  • Table 104. MEA Allergy Immunotherapy, by Type USD Million (2017-2022)
  • Table 105. MEA Allergy Immunotherapy, by Allergy Type USD Million (2017-2022)
  • Table 106. MEA Allergy Immunotherapy, by Sales Channel USD Million (2017-2022)
  • Table 107. MEA Allergy Immunotherapy, by Allergen USD Million (2017-2022)
  • Table 108. Middle East Allergy Immunotherapy, by Type USD Million (2017-2022)
  • Table 109. Middle East Allergy Immunotherapy, by Allergy Type USD Million (2017-2022)
  • Table 110. Middle East Allergy Immunotherapy, by Sales Channel USD Million (2017-2022)
  • Table 111. Middle East Allergy Immunotherapy, by Allergen USD Million (2017-2022)
  • Table 112. Africa Allergy Immunotherapy, by Type USD Million (2017-2022)
  • Table 113. Africa Allergy Immunotherapy, by Allergy Type USD Million (2017-2022)
  • Table 114. Africa Allergy Immunotherapy, by Sales Channel USD Million (2017-2022)
  • Table 115. Africa Allergy Immunotherapy, by Allergen USD Million (2017-2022)
  • Table 116. North America Allergy Immunotherapy, by Country USD Million (2017-2022)
  • Table 117. North America Allergy Immunotherapy, by Type USD Million (2017-2022)
  • Table 118. North America Allergy Immunotherapy, by Allergy Type USD Million (2017-2022)
  • Table 119. North America Allergy Immunotherapy, by Sales Channel USD Million (2017-2022)
  • Table 120. North America Allergy Immunotherapy, by Allergen USD Million (2017-2022)
  • Table 121. United States Allergy Immunotherapy, by Type USD Million (2017-2022)
  • Table 122. United States Allergy Immunotherapy, by Allergy Type USD Million (2017-2022)
  • Table 123. United States Allergy Immunotherapy, by Sales Channel USD Million (2017-2022)
  • Table 124. United States Allergy Immunotherapy, by Allergen USD Million (2017-2022)
  • Table 125. Canada Allergy Immunotherapy, by Type USD Million (2017-2022)
  • Table 126. Canada Allergy Immunotherapy, by Allergy Type USD Million (2017-2022)
  • Table 127. Canada Allergy Immunotherapy, by Sales Channel USD Million (2017-2022)
  • Table 128. Canada Allergy Immunotherapy, by Allergen USD Million (2017-2022)
  • Table 129. Mexico Allergy Immunotherapy, by Type USD Million (2017-2022)
  • Table 130. Mexico Allergy Immunotherapy, by Allergy Type USD Million (2017-2022)
  • Table 131. Mexico Allergy Immunotherapy, by Sales Channel USD Million (2017-2022)
  • Table 132. Mexico Allergy Immunotherapy, by Allergen USD Million (2017-2022)
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Company Basic Information, Sales Area and Its Competitors
  • Table 143. Allergy Immunotherapy: by Type(USD Million)
  • Table 144. Allergy Immunotherapy Allergy Shots , by Region USD Million (2023-2028)
  • Table 145. Allergy Immunotherapy Sublingual Immunotherapy , by Region USD Million (2023-2028)
  • Table 146. Allergy Immunotherapy Medications , by Region USD Million (2023-2028)
  • Table 147. Allergy Immunotherapy Intranasal Immunotherapy , by Region USD Million (2023-2028)
  • Table 148. Allergy Immunotherapy: by Allergy Type(USD Million)
  • Table 149. Allergy Immunotherapy Asthma , by Region USD Million (2023-2028)
  • Table 150. Allergy Immunotherapy Allergic Rhinitis , by Region USD Million (2023-2028)
  • Table 151. Allergy Immunotherapy Atopic Dermatitis , by Region USD Million (2023-2028)
  • Table 152. Allergy Immunotherapy Seasonal Allergies , by Region USD Million (2023-2028)
  • Table 153. Allergy Immunotherapy Insect Venom Allergy , by Region USD Million (2023-2028)
  • Table 154. Allergy Immunotherapy Food Allergy , by Region USD Million (2023-2028)
  • Table 155. Allergy Immunotherapy Others , by Region USD Million (2023-2028)
  • Table 156. Allergy Immunotherapy: by Sales Channel(USD Million)
  • Table 157. Allergy Immunotherapy Online , by Region USD Million (2023-2028)
  • Table 158. Allergy Immunotherapy Offline , by Region USD Million (2023-2028)
  • Table 159. Allergy Immunotherapy: by Allergen(USD Million)
  • Table 160. Allergy Immunotherapy Pollen , by Region USD Million (2023-2028)
  • Table 161. Allergy Immunotherapy Mold/Fungi , by Region USD Million (2023-2028)
  • Table 162. Allergy Immunotherapy Animal Dander , by Region USD Million (2023-2028)
  • Table 163. Allergy Immunotherapy Dust Mites , by Region USD Million (2023-2028)
  • Table 164. Allergy Immunotherapy Insects Venom (Bees, Wasps, Hornets, Yellow Jackets) , by Region USD Million (2023-2028)
  • Table 165. Allergy Immunotherapy Others , by Region USD Million (2023-2028)
  • Table 166. South America Allergy Immunotherapy, by Country USD Million (2023-2028)
  • Table 167. South America Allergy Immunotherapy, by Type USD Million (2023-2028)
  • Table 168. South America Allergy Immunotherapy, by Allergy Type USD Million (2023-2028)
  • Table 169. South America Allergy Immunotherapy, by Sales Channel USD Million (2023-2028)
  • Table 170. South America Allergy Immunotherapy, by Allergen USD Million (2023-2028)
  • Table 171. Brazil Allergy Immunotherapy, by Type USD Million (2023-2028)
  • Table 172. Brazil Allergy Immunotherapy, by Allergy Type USD Million (2023-2028)
  • Table 173. Brazil Allergy Immunotherapy, by Sales Channel USD Million (2023-2028)
  • Table 174. Brazil Allergy Immunotherapy, by Allergen USD Million (2023-2028)
  • Table 175. Argentina Allergy Immunotherapy, by Type USD Million (2023-2028)
  • Table 176. Argentina Allergy Immunotherapy, by Allergy Type USD Million (2023-2028)
  • Table 177. Argentina Allergy Immunotherapy, by Sales Channel USD Million (2023-2028)
  • Table 178. Argentina Allergy Immunotherapy, by Allergen USD Million (2023-2028)
  • Table 179. Rest of South America Allergy Immunotherapy, by Type USD Million (2023-2028)
  • Table 180. Rest of South America Allergy Immunotherapy, by Allergy Type USD Million (2023-2028)
  • Table 181. Rest of South America Allergy Immunotherapy, by Sales Channel USD Million (2023-2028)
  • Table 182. Rest of South America Allergy Immunotherapy, by Allergen USD Million (2023-2028)
  • Table 183. Asia Pacific Allergy Immunotherapy, by Country USD Million (2023-2028)
  • Table 184. Asia Pacific Allergy Immunotherapy, by Type USD Million (2023-2028)
  • Table 185. Asia Pacific Allergy Immunotherapy, by Allergy Type USD Million (2023-2028)
  • Table 186. Asia Pacific Allergy Immunotherapy, by Sales Channel USD Million (2023-2028)
  • Table 187. Asia Pacific Allergy Immunotherapy, by Allergen USD Million (2023-2028)
  • Table 188. China Allergy Immunotherapy, by Type USD Million (2023-2028)
  • Table 189. China Allergy Immunotherapy, by Allergy Type USD Million (2023-2028)
  • Table 190. China Allergy Immunotherapy, by Sales Channel USD Million (2023-2028)
  • Table 191. China Allergy Immunotherapy, by Allergen USD Million (2023-2028)
  • Table 192. Japan Allergy Immunotherapy, by Type USD Million (2023-2028)
  • Table 193. Japan Allergy Immunotherapy, by Allergy Type USD Million (2023-2028)
  • Table 194. Japan Allergy Immunotherapy, by Sales Channel USD Million (2023-2028)
  • Table 195. Japan Allergy Immunotherapy, by Allergen USD Million (2023-2028)
  • Table 196. India Allergy Immunotherapy, by Type USD Million (2023-2028)
  • Table 197. India Allergy Immunotherapy, by Allergy Type USD Million (2023-2028)
  • Table 198. India Allergy Immunotherapy, by Sales Channel USD Million (2023-2028)
  • Table 199. India Allergy Immunotherapy, by Allergen USD Million (2023-2028)
  • Table 200. South Korea Allergy Immunotherapy, by Type USD Million (2023-2028)
  • Table 201. South Korea Allergy Immunotherapy, by Allergy Type USD Million (2023-2028)
  • Table 202. South Korea Allergy Immunotherapy, by Sales Channel USD Million (2023-2028)
  • Table 203. South Korea Allergy Immunotherapy, by Allergen USD Million (2023-2028)
  • Table 204. Taiwan Allergy Immunotherapy, by Type USD Million (2023-2028)
  • Table 205. Taiwan Allergy Immunotherapy, by Allergy Type USD Million (2023-2028)
  • Table 206. Taiwan Allergy Immunotherapy, by Sales Channel USD Million (2023-2028)
  • Table 207. Taiwan Allergy Immunotherapy, by Allergen USD Million (2023-2028)
  • Table 208. Australia Allergy Immunotherapy, by Type USD Million (2023-2028)
  • Table 209. Australia Allergy Immunotherapy, by Allergy Type USD Million (2023-2028)
  • Table 210. Australia Allergy Immunotherapy, by Sales Channel USD Million (2023-2028)
  • Table 211. Australia Allergy Immunotherapy, by Allergen USD Million (2023-2028)
  • Table 212. Rest of Asia-Pacific Allergy Immunotherapy, by Type USD Million (2023-2028)
  • Table 213. Rest of Asia-Pacific Allergy Immunotherapy, by Allergy Type USD Million (2023-2028)
  • Table 214. Rest of Asia-Pacific Allergy Immunotherapy, by Sales Channel USD Million (2023-2028)
  • Table 215. Rest of Asia-Pacific Allergy Immunotherapy, by Allergen USD Million (2023-2028)
  • Table 216. Europe Allergy Immunotherapy, by Country USD Million (2023-2028)
  • Table 217. Europe Allergy Immunotherapy, by Type USD Million (2023-2028)
  • Table 218. Europe Allergy Immunotherapy, by Allergy Type USD Million (2023-2028)
  • Table 219. Europe Allergy Immunotherapy, by Sales Channel USD Million (2023-2028)
  • Table 220. Europe Allergy Immunotherapy, by Allergen USD Million (2023-2028)
  • Table 221. Germany Allergy Immunotherapy, by Type USD Million (2023-2028)
  • Table 222. Germany Allergy Immunotherapy, by Allergy Type USD Million (2023-2028)
  • Table 223. Germany Allergy Immunotherapy, by Sales Channel USD Million (2023-2028)
  • Table 224. Germany Allergy Immunotherapy, by Allergen USD Million (2023-2028)
  • Table 225. France Allergy Immunotherapy, by Type USD Million (2023-2028)
  • Table 226. France Allergy Immunotherapy, by Allergy Type USD Million (2023-2028)
  • Table 227. France Allergy Immunotherapy, by Sales Channel USD Million (2023-2028)
  • Table 228. France Allergy Immunotherapy, by Allergen USD Million (2023-2028)
  • Table 229. Italy Allergy Immunotherapy, by Type USD Million (2023-2028)
  • Table 230. Italy Allergy Immunotherapy, by Allergy Type USD Million (2023-2028)
  • Table 231. Italy Allergy Immunotherapy, by Sales Channel USD Million (2023-2028)
  • Table 232. Italy Allergy Immunotherapy, by Allergen USD Million (2023-2028)
  • Table 233. United Kingdom Allergy Immunotherapy, by Type USD Million (2023-2028)
  • Table 234. United Kingdom Allergy Immunotherapy, by Allergy Type USD Million (2023-2028)
  • Table 235. United Kingdom Allergy Immunotherapy, by Sales Channel USD Million (2023-2028)
  • Table 236. United Kingdom Allergy Immunotherapy, by Allergen USD Million (2023-2028)
  • Table 237. Netherlands Allergy Immunotherapy, by Type USD Million (2023-2028)
  • Table 238. Netherlands Allergy Immunotherapy, by Allergy Type USD Million (2023-2028)
  • Table 239. Netherlands Allergy Immunotherapy, by Sales Channel USD Million (2023-2028)
  • Table 240. Netherlands Allergy Immunotherapy, by Allergen USD Million (2023-2028)
  • Table 241. Rest of Europe Allergy Immunotherapy, by Type USD Million (2023-2028)
  • Table 242. Rest of Europe Allergy Immunotherapy, by Allergy Type USD Million (2023-2028)
  • Table 243. Rest of Europe Allergy Immunotherapy, by Sales Channel USD Million (2023-2028)
  • Table 244. Rest of Europe Allergy Immunotherapy, by Allergen USD Million (2023-2028)
  • Table 245. MEA Allergy Immunotherapy, by Country USD Million (2023-2028)
  • Table 246. MEA Allergy Immunotherapy, by Type USD Million (2023-2028)
  • Table 247. MEA Allergy Immunotherapy, by Allergy Type USD Million (2023-2028)
  • Table 248. MEA Allergy Immunotherapy, by Sales Channel USD Million (2023-2028)
  • Table 249. MEA Allergy Immunotherapy, by Allergen USD Million (2023-2028)
  • Table 250. Middle East Allergy Immunotherapy, by Type USD Million (2023-2028)
  • Table 251. Middle East Allergy Immunotherapy, by Allergy Type USD Million (2023-2028)
  • Table 252. Middle East Allergy Immunotherapy, by Sales Channel USD Million (2023-2028)
  • Table 253. Middle East Allergy Immunotherapy, by Allergen USD Million (2023-2028)
  • Table 254. Africa Allergy Immunotherapy, by Type USD Million (2023-2028)
  • Table 255. Africa Allergy Immunotherapy, by Allergy Type USD Million (2023-2028)
  • Table 256. Africa Allergy Immunotherapy, by Sales Channel USD Million (2023-2028)
  • Table 257. Africa Allergy Immunotherapy, by Allergen USD Million (2023-2028)
  • Table 258. North America Allergy Immunotherapy, by Country USD Million (2023-2028)
  • Table 259. North America Allergy Immunotherapy, by Type USD Million (2023-2028)
  • Table 260. North America Allergy Immunotherapy, by Allergy Type USD Million (2023-2028)
  • Table 261. North America Allergy Immunotherapy, by Sales Channel USD Million (2023-2028)
  • Table 262. North America Allergy Immunotherapy, by Allergen USD Million (2023-2028)
  • Table 263. United States Allergy Immunotherapy, by Type USD Million (2023-2028)
  • Table 264. United States Allergy Immunotherapy, by Allergy Type USD Million (2023-2028)
  • Table 265. United States Allergy Immunotherapy, by Sales Channel USD Million (2023-2028)
  • Table 266. United States Allergy Immunotherapy, by Allergen USD Million (2023-2028)
  • Table 267. Canada Allergy Immunotherapy, by Type USD Million (2023-2028)
  • Table 268. Canada Allergy Immunotherapy, by Allergy Type USD Million (2023-2028)
  • Table 269. Canada Allergy Immunotherapy, by Sales Channel USD Million (2023-2028)
  • Table 270. Canada Allergy Immunotherapy, by Allergen USD Million (2023-2028)
  • Table 271. Mexico Allergy Immunotherapy, by Type USD Million (2023-2028)
  • Table 272. Mexico Allergy Immunotherapy, by Allergy Type USD Million (2023-2028)
  • Table 273. Mexico Allergy Immunotherapy, by Sales Channel USD Million (2023-2028)
  • Table 274. Mexico Allergy Immunotherapy, by Allergen USD Million (2023-2028)
  • Table 275. Research Programs/Design for This Report
  • Table 276. Key Data Information from Secondary Sources
  • Table 277. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Allergy Immunotherapy: by Type USD Million (2017-2022)
  • Figure 5. Global Allergy Immunotherapy: by Allergy Type USD Million (2017-2022)
  • Figure 6. Global Allergy Immunotherapy: by Sales Channel USD Million (2017-2022)
  • Figure 7. Global Allergy Immunotherapy: by Allergen USD Million (2017-2022)
  • Figure 8. South America Allergy Immunotherapy Share (%), by Country
  • Figure 9. Asia Pacific Allergy Immunotherapy Share (%), by Country
  • Figure 10. Europe Allergy Immunotherapy Share (%), by Country
  • Figure 11. MEA Allergy Immunotherapy Share (%), by Country
  • Figure 12. North America Allergy Immunotherapy Share (%), by Country
  • Figure 13. Global Allergy Immunotherapy share by Players 2022 (%)
  • Figure 14. Global Allergy Immunotherapy share by Players (Top 3) 2022(%)
  • Figure 15. Global Allergy Immunotherapy share by Players (Top 5) 2022(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. ALK Revenue, Net Income and Gross profit
  • Figure 18. ALK Revenue: by Geography 2022
  • Figure 19. HAL Allergy Group Revenue, Net Income and Gross profit
  • Figure 20. HAL Allergy Group Revenue: by Geography 2022
  • Figure 21. Merck KGaA?Allergopharma? Revenue, Net Income and Gross profit
  • Figure 22. Merck KGaA?Allergopharma? Revenue: by Geography 2022
  • Figure 23. Stallergenes Greer Revenue, Net Income and Gross profit
  • Figure 24. Stallergenes Greer Revenue: by Geography 2022
  • Figure 25. Circassia Revenue, Net Income and Gross profit
  • Figure 26. Circassia Revenue: by Geography 2022
  • Figure 27. DBV Technologies. Revenue, Net Income and Gross profit
  • Figure 28. DBV Technologies. Revenue: by Geography 2022
  • Figure 29. Aimmune Therapeutics Revenue, Net Income and Gross profit
  • Figure 30. Aimmune Therapeutics Revenue: by Geography 2022
  • Figure 31. Biomay AG Revenue, Net Income and Gross profit
  • Figure 32. Biomay AG Revenue: by Geography 2022
  • Figure 33. Anergis Revenue, Net Income and Gross profit
  • Figure 34. Anergis Revenue: by Geography 2022
  • Figure 35. Allergy Therapeutics Revenue, Net Income and Gross profit
  • Figure 36. Allergy Therapeutics Revenue: by Geography 2022
  • Figure 37. Global Allergy Immunotherapy: by Type USD Million (2023-2028)
  • Figure 38. Global Allergy Immunotherapy: by Allergy Type USD Million (2023-2028)
  • Figure 39. Global Allergy Immunotherapy: by Sales Channel USD Million (2023-2028)
  • Figure 40. Global Allergy Immunotherapy: by Allergen USD Million (2023-2028)
  • Figure 41. South America Allergy Immunotherapy Share (%), by Country
  • Figure 42. Asia Pacific Allergy Immunotherapy Share (%), by Country
  • Figure 43. Europe Allergy Immunotherapy Share (%), by Country
  • Figure 44. MEA Allergy Immunotherapy Share (%), by Country
  • Figure 45. North America Allergy Immunotherapy Share (%), by Country
List of companies from research coverage that are profiled in the study
  • ALK
  • HAL Allergy Group
  • Merck KGaA?Allergopharma?
  • Stallergenes Greer
  • Circassia
  • DBV Technologies.
  • Aimmune Therapeutics
  • Biomay AG
  • Anergis
  • Allergy Therapeutics
Select User Access Type

Key Highlights of Report


Dec 2023 220 Pages 89 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Allergy Immunotherapy Quantitative research analysis
Global Allergy Immunotherapy Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Allergy Immunotherapy market are ALK, HAL Allergy Group, Merck KGaA?Allergopharma?, Stallergenes Greer, Circassia, DBV Technologies., Aimmune Therapeutics, Biomay AG, Anergis and Allergy Therapeutics, to name a few.
"" is seen as one of major influencing trends for Allergy Immunotherapy Market during projected period 2022-2028.
Allergy Shots segment in Global market to hold robust market share owing to "".

Know More About Global Allergy Immunotherapy Report?

Have a Query? Click Here

Other Related Reports

Education Marketing Services Comprehensive Study by Type (Online modes, Offline modes), Application (Educational institutions, Ed-tech companies) Players and Region - Global Market Outlook to 2026
$ 3500
Telecom API Comprehensive Study by Type (SMS, MMS, and RCS API, WebRTC API, Payment API, Content Delivery API, ID/SSO and subscriber API, IVR/voice store and voice control API, M2M and IoT API, Locat...
$ 3750
Helicopter Simulator Comprehensive Study by Type (Motion Simulator, Fixed-Base Simulator, Others), Application (Commercial, Military, Others), Distribution Channel (Online Retail, Offline Retail), C...
$ 3450
Professional A2P SMS Comprehensive Study by Application (Customer relationship management (CRM) services, Pushed Content Services, Promotional Campaigns, Interactive Messaging Service, Others), Traff...
$ 3800
Military Communications Comprehensive Study by Type (Security System, Military Satcom, Radio System), Application (Land Forces, Naval Forces, Air Forces), Communication Type (Airborne Communications,...
$ 3650
Pipeline Sampler Comprehensive Study by Type (Gas Samplers, Natural gas, Others, Liquid Samplers, Crude Oil, Light Liquid, Petrochemicals, LNG& CNG, Others), Application (Oil Pipeline Sampling, Marin...
$ 3800